HUE062552T2 - ADAM6 egerek - Google Patents

ADAM6 egerek

Info

Publication number
HUE062552T2
HUE062552T2 HUE22156414A HUE22156414A HUE062552T2 HU E062552 T2 HUE062552 T2 HU E062552T2 HU E22156414 A HUE22156414 A HU E22156414A HU E22156414 A HUE22156414 A HU E22156414A HU E062552 T2 HUE062552 T2 HU E062552T2
Authority
HU
Hungary
Prior art keywords
adam6 mice
adam6
mice
Prior art date
Application number
HUE22156414A
Other languages
English (en)
Hungarian (hu)
Inventor
Lynn Macdonald
Sean Stevens
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE062552(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HUE062552T2 publication Critical patent/HUE062552T2/hu

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/22—Heating, cooling or ventilating [HVAC] devices the heat being derived otherwise than from the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mechanical Engineering (AREA)
  • Thermal Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
HUE22156414A 2011-02-25 2012-02-24 ADAM6 egerek HUE062552T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06

Publications (1)

Publication Number Publication Date
HUE062552T2 true HUE062552T2 (hu) 2023-11-28

Family

ID=45998616

Family Applications (5)

Application Number Title Priority Date Filing Date
HUE22156414A HUE062552T2 (hu) 2011-02-25 2012-02-24 ADAM6 egerek
HUE12192727A HUE046081T2 (hu) 2011-02-25 2012-02-24 Adam6 egér
HUE14154918A HUE046746T2 (hu) 2011-02-25 2012-02-24 Adam6 egér
HUE12716101A HUE024534T2 (hu) 2011-02-25 2012-02-24 ADAM6 egerek
HUE14154967A HUE047687T2 (hu) 2011-02-25 2012-02-24 ADAM6 egér

Family Applications After (4)

Application Number Title Priority Date Filing Date
HUE12192727A HUE046081T2 (hu) 2011-02-25 2012-02-24 Adam6 egér
HUE14154918A HUE046746T2 (hu) 2011-02-25 2012-02-24 Adam6 egér
HUE12716101A HUE024534T2 (hu) 2011-02-25 2012-02-24 ADAM6 egerek
HUE14154967A HUE047687T2 (hu) 2011-02-25 2012-02-24 ADAM6 egér

Country Status (31)

Country Link
US (12) US8642835B2 (enExample)
EP (7) EP3744850A1 (enExample)
JP (8) JP2014507137A (enExample)
KR (1) KR101387377B1 (enExample)
CN (2) CN105861548B (enExample)
AU (5) AU2012243291B2 (enExample)
BR (1) BR112013021771B1 (enExample)
CA (1) CA2820824A1 (enExample)
CY (5) CY1116301T1 (enExample)
DE (5) DE14154967T1 (enExample)
DK (6) DK2813573T1 (enExample)
ES (6) ES2758974T5 (enExample)
FI (3) FI2738258T4 (enExample)
HR (5) HRP20192311T4 (enExample)
HU (5) HUE062552T2 (enExample)
IL (4) IL226727A (enExample)
IN (1) IN2013CN07629A (enExample)
LT (4) LT2738258T (enExample)
ME (3) ME02106B (enExample)
MX (3) MX375115B (enExample)
MY (1) MY172713A (enExample)
NZ (2) NZ776770A (enExample)
PL (5) PL2738259T3 (enExample)
PT (5) PT2738259T (enExample)
RS (5) RS59413B2 (enExample)
RU (2) RU2582261C2 (enExample)
SG (4) SG192933A1 (enExample)
SI (5) SI2578688T2 (enExample)
SM (5) SMT202300173T1 (enExample)
WO (1) WO2012141798A1 (enExample)
ZA (1) ZA201305998B (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
WO2006008548A2 (en) 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP3028565B1 (en) 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
RU2612903C2 (ru) 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
DK2813573T1 (da) 2011-02-25 2015-01-12 Regeneron Pharma ADAM6 mus
EP2739300B1 (en) 2011-07-05 2019-06-19 Duke University N-terminal deleted gp120 immunogens
HUE068728T2 (hu) * 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
JP2014531452A (ja) 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
PL3216871T3 (pl) * 2011-10-17 2022-03-21 Regeneron Pharmaceuticals, Inc. Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
US20180295821A1 (en) * 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
MX378871B (es) 2011-12-20 2025-03-10 Regeneron Pharma Ratones con cadena ligera humanizada.
PL2809150T3 (pl) * 2012-02-01 2020-04-30 Regeneron Pharmaceuticals, Inc. Humanizowane myszy wykazujące ekspresję łańcuchów ciężkich zawierających domeny VL
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
EP3348140B1 (en) 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
CA2865644A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
EP2858487B1 (en) * 2012-06-12 2019-10-23 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
MX357061B (es) 2013-02-06 2018-06-25 Regeneron Pharma Diseño de inmunogenos a base de linaje de celulas b con animales humanizados.
RS57582B1 (sr) 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
EP2967012B1 (en) * 2013-03-14 2020-09-16 Erasmus University Medical Center Rotterdam Transgenic non-human mammal for antibody production
WO2014141192A1 (en) * 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
RU2016141307A (ru) * 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
KR20170083534A (ko) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
IL260526B2 (en) * 2016-01-13 2023-10-01 Regeneron Pharma Rodents having an engineered heavy chain diversity region
EP3416479A1 (en) 2016-02-16 2018-12-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
IL263160B2 (en) 2016-06-03 2024-01-01 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
MA53935A (fr) 2016-11-04 2021-12-22 Regeneron Pharma Animaux non humains ayant un locus à chaîne légère lambda d'immunoglobuline modifiée
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
CN110809583A (zh) 2017-06-07 2020-02-18 瑞泽恩制药公司 用于内化酶的组合物和方法
PL3720279T3 (pl) 2017-12-05 2023-01-16 Regeneron Pharmaceuticals, Inc. Myszy posiadające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny oraz ich zastosowania
KR20200118151A (ko) 2018-02-07 2020-10-14 리제너론 파마슈티칼스 인코포레이티드 치료 단백질 전달을 위한 방법 및 조성물
EP3768079A4 (en) 2018-03-21 2021-12-08 Crystal Bioscience Inc. TRANSGENIC CHICKEN THAT PRODUCES HUMAN ANTIBODIES
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
JP7420730B2 (ja) 2018-04-06 2024-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体
MX2020012350A (es) 2018-05-17 2021-01-29 Regeneron Pharma Anticuerpos anti-cd63, conjugados y usos de estos.
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
AU2020226445B2 (en) 2019-02-18 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
EP3927153A1 (en) 2019-02-22 2021-12-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
CA3136478A1 (en) 2019-06-05 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
DK3785536T4 (da) * 2019-08-28 2025-10-27 Trianni Inc Adam6-knockin-mus
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
AU2021283564B2 (en) 2020-06-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
AU2021409906A1 (en) 2020-12-23 2023-06-15 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
JP7758739B2 (ja) 2020-12-23 2025-10-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンカー改変型抗体をコードする核酸およびその使用
CN117177993B (zh) 2021-04-20 2025-06-20 瑞泽恩制药公司 针对artemin的人抗体及其使用方法
EP4554977A1 (en) 2022-07-12 2025-05-21 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
AU2024220647A1 (en) 2023-02-13 2025-08-21 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies
WO2024229105A1 (en) 2023-05-02 2024-11-07 Regeneron Pharmaceuticals, Inc. Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
WO2025014533A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof
WO2025055311A1 (zh) 2023-09-15 2025-03-20 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法
KR20250151517A (ko) * 2023-09-15 2025-10-21 사이어젠 바이오싸이언스이즈 (쑤저우) 인코퍼레이티드 항체 제조를 위한 유전자 변형 마우스 및 이의 제조 방법
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
KR20250108092A (ko) * 2024-01-02 2025-07-15 젬파마테크 컴퍼니 리미티드 인간화 항체를 생성하는 동물 모델 및 그 제작 방법

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH08503617A (ja) * 1992-12-01 1996-04-23 プロテイン デザイン ラブズ、インコーポレーテッド Ｌ−セレクチンに反応性のヒト化抗体
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
JP2003501016A (ja) * 1999-05-27 2003-01-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ａｄａｍのポリヌクレオチドおよびポリペプチド
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
DE60227067D1 (de) 2001-05-11 2008-07-24 Kirin Pharma Kk Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
EP1739691B1 (en) 2005-06-30 2008-12-03 Borealis Technology Oy Outer sheath layer for power or communication cable
EP2505058A1 (en) * 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
US9693539B2 (en) 2007-08-10 2017-07-04 E. R. Squibb & Sons, L.L.C. HCO32 and HCO27 and related examples
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
EP3028565B1 (en) * 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
US8754287B2 (en) 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
SMT201900372T1 (it) 2010-02-08 2019-09-09 Regeneron Pharma Topo con catena leggera comune
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
NZ605966A (en) * 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
DK2813573T1 (da) 2011-02-25 2015-01-12 Regeneron Pharma ADAM6 mus
HUE068728T2 (hu) 2011-08-05 2025-01-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
PL3216871T3 (pl) 2011-10-17 2022-03-21 Regeneron Pharmaceuticals, Inc. Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
MX378871B (es) 2011-12-20 2025-03-10 Regeneron Pharma Ratones con cadena ligera humanizada.
EP2858487B1 (en) 2012-06-12 2019-10-23 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci

Also Published As

Publication number Publication date
ES2748832T3 (es) 2020-03-18
SG10201913155QA (en) 2020-02-27
IL268671B (en) 2020-05-31
EP2550363A1 (en) 2013-01-30
SI2578688T2 (sl) 2023-05-31
WO2012141798A1 (en) 2012-10-18
CN105861548B (zh) 2020-01-10
EP2578688B1 (en) 2019-07-24
MX375115B (es) 2025-03-06
HRP20230526T1 (hr) 2023-09-01
SMT202000112T1 (it) 2020-05-08
ES2758974T5 (es) 2023-06-08
DK2738259T1 (da) 2014-11-24
EP4067496B1 (en) 2023-03-29
SMT201500061B (it) 2015-05-05
US10072095B2 (en) 2018-09-11
SI2738258T1 (sl) 2020-01-31
HUE024534T2 (hu) 2016-01-28
AU2012243291A1 (en) 2013-05-09
EP4067496A1 (en) 2022-10-05
IL261243A (en) 2018-10-31
CY1122459T1 (el) 2021-01-27
NZ703609A (en) 2016-04-29
CY1116301T1 (el) 2017-02-08
SI4067496T1 (sl) 2023-07-31
DE12192727T1 (de) 2013-07-11
PL2578688T5 (pl) 2023-05-29
PT2738259T (pt) 2020-02-18
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
AU2022206806B2 (en) 2025-10-02
NZ731926A (en) 2021-07-30
MY172713A (en) 2019-12-11
SI2738258T2 (sl) 2023-05-31
DK2738258T4 (da) 2023-05-08
PT2738258T (pt) 2019-12-10
US20120322108A1 (en) 2012-12-20
CN105861548A (zh) 2016-08-17
DK2813573T1 (da) 2015-01-12
DK4067496T5 (da) 2024-07-22
HUE046746T2 (hu) 2020-03-30
NZ797720A (en) 2024-09-27
AU2012243291B2 (en) 2015-07-09
RU2722373C2 (ru) 2020-05-29
ES2805364T3 (es) 2021-02-11
RU2582261C2 (ru) 2016-04-20
EP3744850A1 (en) 2020-12-02
HRP20192311T1 (hr) 2020-03-20
SI2738259T1 (sl) 2020-06-30
JP2022071051A (ja) 2022-05-13
US10694725B2 (en) 2020-06-30
CY1126091T1 (el) 2023-11-15
IL268671A (en) 2019-10-31
MX343009B (es) 2016-10-21
EP2738258B1 (en) 2019-09-25
DK2738258T3 (da) 2019-12-16
CY1122820T1 (el) 2021-05-05
US9944716B2 (en) 2018-04-17
DE14154918T1 (de) 2014-08-21
IL273986B (en) 2021-04-29
SG10201405135RA (en) 2014-10-30
RS59661B2 (sr) 2023-06-30
HK1201292A1 (en) 2015-08-28
EP2813573B1 (en) 2020-04-22
DE14154967T1 (de) 2014-08-28
RU2016109443A (ru) 2018-11-26
US8642835B2 (en) 2014-02-04
HRP20191895T1 (hr) 2020-01-10
DK2578688T4 (da) 2023-05-08
SG10201913160QA (en) 2020-03-30
PT4067496T (pt) 2023-06-07
ES2758974T3 (es) 2020-05-07
HUE046081T2 (hu) 2020-01-28
JP2014110814A (ja) 2014-06-19
SMT202300173T1 (it) 2023-07-20
IL273986A (en) 2020-05-31
PL2738258T3 (pl) 2020-08-24
ZA201305998B (en) 2016-07-27
LT4067496T (lt) 2023-06-12
DE14176593T1 (de) 2015-03-05
JP2018143250A (ja) 2018-09-20
EP2738258A3 (en) 2014-09-24
US20210105984A1 (en) 2021-04-15
RS59661B1 (sr) 2020-01-31
ES2770424T3 (es) 2020-07-01
US12207628B2 (en) 2025-01-28
US20180346599A1 (en) 2018-12-06
US10905108B2 (en) 2021-02-02
HUE047687T2 (hu) 2020-05-28
NZ718688A (en) 2017-07-28
ME03732B (me) 2021-01-20
JP2014507137A (ja) 2014-03-27
HRP20191895T4 (hr) 2023-05-12
FI2738258T4 (fi) 2023-05-05
DK2550363T3 (en) 2015-03-23
HK1174490A1 (en) 2013-06-14
US20240306617A1 (en) 2024-09-19
CA2820824A1 (en) 2012-10-18
IL226727A (en) 2016-08-31
US20210105985A1 (en) 2021-04-15
ES2946169T3 (es) 2023-07-13
PL2578688T3 (pl) 2020-05-18
FI2578688T4 (fi) 2023-05-05
PT2550363E (pt) 2015-03-16
RU2013125717A (ru) 2014-12-10
US20130254911A1 (en) 2013-09-26
PL2550363T3 (pl) 2015-05-29
ME02106B (me) 2015-10-20
US20180362663A1 (en) 2018-12-20
DK4067496T3 (da) 2023-06-26
EP2738258A2 (en) 2014-06-04
CN103429746A (zh) 2013-12-04
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09
ES2748832T5 (es) 2023-06-08
US8697940B2 (en) 2014-04-15
EP2738258B2 (en) 2023-02-01
AU2017251802A1 (en) 2017-11-16
EP2578688A1 (en) 2013-04-10
KR20130116375A (ko) 2013-10-23
US20150210776A1 (en) 2015-07-30
KR101387377B1 (ko) 2014-04-21
HRP20192311T4 (hr) 2023-05-12
NZ776770A (en) 2023-03-31
SMT201900581T1 (it) 2019-11-13
SG192933A1 (en) 2013-09-30
HRP20150262T1 (hr) 2015-04-10
JP2016135143A (ja) 2016-07-28
ES2532487T3 (es) 2015-03-27
DK2578688T1 (da) 2014-11-24
DE12716101T1 (de) 2013-05-08
US20180345760A1 (en) 2018-12-06
LT2578688T (lt) 2019-11-11
EP2738259A3 (en) 2014-07-30
AU2015238806A1 (en) 2015-10-29
HRP20200294T1 (hr) 2020-05-29
LT2738258T (lt) 2020-01-10
EP2738259B1 (en) 2019-11-27
NZ612643A (en) 2015-06-26
US20150201589A1 (en) 2015-07-23
RS64280B1 (sr) 2023-07-31
LT2738259T (lt) 2020-03-10
RU2016109443A3 (enExample) 2019-07-24
IL261243B (en) 2019-08-29
DK2578688T3 (da) 2019-10-28
EP2550363B1 (en) 2014-12-10
JP2015107131A (ja) 2015-06-11
DK2738258T1 (da) 2014-11-24
SMT201900744T1 (it) 2020-01-14
MX2013009649A (es) 2013-09-26
US10577430B2 (en) 2020-03-03
AU2022206806A1 (en) 2022-08-18
DK2738259T3 (da) 2020-02-17
EP2738259A2 (en) 2014-06-04
BR112013021771A2 (pt) 2017-07-04
US10905109B2 (en) 2021-02-02
US20140213773A1 (en) 2014-07-31
RS59413B2 (sr) 2023-06-30
SI2578688T1 (sl) 2019-11-29
IN2013CN07629A (enExample) 2015-08-07
RS53880B1 (sr) 2015-08-31
CY1122205T1 (el) 2020-11-25
RS59929B1 (sr) 2020-03-31
US9932408B2 (en) 2018-04-03
RS59413B1 (sr) 2019-11-29
MX2020009714A (es) 2020-10-07
CN103429746B (zh) 2016-05-11
PL4067496T3 (pl) 2023-07-31
PL2738259T3 (pl) 2020-08-24
JP5866127B2 (ja) 2016-02-17
FI4067496T3 (fi) 2023-05-24
EP2813573A1 (en) 2014-12-17
ME03537B (enExample) 2020-04-20
US20180346598A1 (en) 2018-12-06
JP2025032218A (ja) 2025-03-11
JP2019187446A (ja) 2019-10-31
EP2578688B2 (en) 2023-02-08
BR112013021771B1 (pt) 2022-11-16
AU2020201279A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
IL273986B (en) adam6 mice
DK2691417T4 (en) Antistof fc-varianter
AP2014007621A0 (en) 2-Thiopyrimidinones
DK2770906T3 (en) Applanationstonometer
AU339404S (en) Pen
AU4540P (en) BUNNAN Baloskion tetraphyllum
AU5171P (en) Sunparamiho Mandevilla xamabilis
AU5031P (en) BESYS Beschorneria yuccoides
AU5026P (en) Goldstrike Agapanthus inapertus
GB201109865D0 (en) Touchiness interaction
AP00723S1 (en) Autorickshaw
AP2011000390S (en) Kuppkraft
AU339857S (en) Orchidometer
AU338420S (en) Kettlebell
AU2011035V (en) DBK02 Babingtonia virgata
AU2011303V (en) Silverado Dianella tasmanica
AU338110S (en) Barstool